Skip to content
2000
image of Rheumatoid Arthritis: Pathogenesis, Therapeutic Strategies, Advances, and Structural Activity Relationships of Synthesized Agents

Abstract

Rheumatoid arthritis (RA) is the most prevalent form of inflammatory arthritis, characterized by chronic inflammation of the synovial membrane. Current therapeutic options have advanced RA management significantly, yet limitations like adverse effects and treatment resistance underscore the need for novel therapeutic agents. Recent advancements have introduced promising candidates, including BTK inhibitors, JAK inhibitors, TLR4 inhibitors, COX-2 inhibitors, and LOX inhibitors, which target specific pathways implicated in RA pathogenesis. This manuscript provides a comprehensive overview of RA, emphasizing its pathophysiology, diagnostic approaches, and therapeutic strategies. Special attention is given to the structural-activity relationships (SAR) and mechanistic insights underlying emerging pharmacological interventions. Moreover, current challenges and future directions in RA drug discovery are critically examined, highlighting innovative wet-lab approaches to address unmet clinical needs.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ctmc/10.2174/0115680266346339250328153358
2025-04-14
2025-09-13

  • From This Site

    /content/journals/ctmc/10.2174/0115680266346339250328153358
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Almasi S. Aslani S. Poormoghim H. Jamshidi A.R. Poursani S. Mahmoudi M. Gene expression profiling of toll-like receptor 4 and 5 in peripheral blood mononuclear cells in rheumatic disorders: Ankylosing spondylitis and rheumatoid arthritis. Iran. J. Allergy Asthma Immunol. 2016 15 1 87 92 26996117
    [Google Scholar]
  2. Mohammadi S.A. Mansouri R. Shahi A. Akhlaghi M. Dashti N. Mansouri S. Aslani S. 2018
  3. Paget S.A. Lockshin M.D. Loebl S. The hospital for special surgery rheumatoid arthritis handbook: everything you need to know 2002
    [Google Scholar]
  4. Senst B. Tadi P. Goyal A. Hypercoagulability. Treasure Island, FL StatPearls 2022
    [Google Scholar]
  5. Mahmoudi M. Aslani S. Fadaei R. Jamshidi A.R. New insights to the mechanisms underlying atherosclerosis in rheumatoid arthritis. Int. J. Rheum. Dis. 2017 20 3 287 297 10.1111/1756‑185X.12999 28205331
    [Google Scholar]
  6. Malmström V. Catrina A.I. Klareskog L. The immunopathogenesis of seropositive rheumatoid arthritis: From triggering to targeting. Nat. Rev. Immunol. 2017 17 1 60 75 10.1038/nri.2016.124 27916980
    [Google Scholar]
  7. Mohammadi H. Sharafkandi N. Hemmatzadeh M. Azizi G. Karimi M. Jadidi-Niaragh F. Baradaran B. Babaloo Z. The role of innate lymphoid cells in health and disease. J. Cell. Physiol. 2018 233 6 4512 4529 10.1002/jcp.26250 29058773
    [Google Scholar]
  8. Mousavi M.J. Jamshidi A. Chopra A. Aslani S. Akhlaghi M. Mahmoudi M. Implications of the noncoding RNAs in rheumatoid arthritis pathogenesis. J. Cell. Physiol. 2019 234 1 335 347 10.1002/jcp.26911 30069877
    [Google Scholar]
  9. Shabgah A.G. Navashenaq J.G. Shabgah O.G. Mohammadi H. Sahebkar A. Interleukin-22 in human inflammatory diseases and viral infections. Autoimmun. Rev. 2017 16 12 1209 1218 10.1016/j.autrev.2017.10.004 29037907
    [Google Scholar]
  10. Trollmo C. Klareskog L. Predicting and assessing an inflammatory disease and its complications: Example from rheumatoid arthritis. Biomarkers in Drug Discovery and Development: A Handbook of Practice, Application, and Strategy. Wiley 2020 365 377 10.1002/9781119187547.ch18
    [Google Scholar]
  11. Edilova M.I. Akram A. Abdul-Sater A.A. Innate immunity drives pathogenesis of rheumatoid arthritis. Biomed. J. 2021 44 2 172 182 10.1016/j.bj.2020.06.010 32798211
    [Google Scholar]
  12. Kumar L.D. Karthik R. Gayathri N. Sivasudha T. Advancement in contemporary diagnostic and therapeutic approaches for rheumatoid arthritis. Biomed. Pharmacother. 2016 79 52 61 10.1016/j.biopha.2016.02.001 27044812
    [Google Scholar]
  13. Hannemann N. Apparailly F. Courties G. Synovial macrophages: From ordinary eaters to extraordinary multitaskers. Trends Immunol. 2021 42 5 368 371 10.1016/j.it.2021.03.002 33832864
    [Google Scholar]
  14. Fang Q. Zhou C. Nandakumar K.S. Molecular and cellular pathways contributing to joint damage in rheumatoid arthritis. Mediators Inflamm. 2020 2020 1 20 10.1155/2020/3830212 32256192
    [Google Scholar]
  15. Guo Q. Wang Y. Xu D. Nossent J. Pavlos N.J. Xu J. Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018 6 1 15 10.1038/s41413‑018‑0016‑9 29736302
    [Google Scholar]
  16. Bartok B. Firestein G.S. Fibroblast‐like synoviocytes: Key effector cells in rheumatoid arthritis. Immunol. Rev. 2010 233 1 233 255 10.1111/j.0105‑2896.2009.00859.x 20193003
    [Google Scholar]
  17. Itoh Y.J.P.i.m.b. 2017
  18. Yasuda T. Cartilage destruction by matrix degradation products. Mod. Rheumatol. 2006 16 4 197 205 10.3109/s10165‑006‑0490‑6 16906368
    [Google Scholar]
  19. Yap H.Y. Tee S.Z.Y. Wong M.M.T. Chow S.K. Peh S.C. Teow S.Y. Pathogenic role of immune cells in rheumatoid arthritis: Implications in clinical treatment and biomarker development. Cells 2018 7 10 161 10.3390/cells7100161 30304822
    [Google Scholar]
  20. Mateen S. Zafar A. Moin S. Khan A.Q. Zubair S. Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis. Clin. Chim. Acta 2016 455 161 171 10.1016/j.cca.2016.02.010 26883280
    [Google Scholar]
  21. Essouma M. Noubiap J.J. Is air pollution a risk factor for rheumatoid arthritis? J. Inflamm. (Lond.) 2015 12 48 10.1186/s12950‑015‑0092‑1
    [Google Scholar]
  22. Alsaber A. Pan J. Al-Herz A. Alkandary D. Al-Hurban A. Setiya P. Influence of ambient air pollution on rheumatoid arthritis disease activity score index. Int. J. Environ. Res. Public Health 2020 17 2 416 10.3390/ijerph17020416 31936295
    [Google Scholar]
  23. Adami G. Viapiana O. Rossini M. Orsolini G. Bertoldo E. Giollo A. Gatti D. Fassio A. Association between environmental air pollution and rheumatoid arthritis flares. Rheumatology (Oxford) 2021 60 10 4591 4597 10.1093/rheumatology/keab049 33470401
    [Google Scholar]
  24. Radu A.F. Bungau S.G. Management of rheumatoid arthritis: An overview. Cells 2021 10 11 2857 10.3390/cells10112857 34831081
    [Google Scholar]
  25. Qindeel M. Ullah M.H. Fakhar-ud-Din; Ahmed, N.; Rehman, A. Recent trends, challenges and future outlook of transdermal drug delivery systems for rheumatoid arthritis therapy. J. Control. Release 2020 327 595 615 10.1016/j.jconrel.2020.09.016 32920080
    [Google Scholar]
  26. Myasoedova E. Crowson C.S. Kremers H.M. Therneau T.M. Gabriel S.E. Is the incidence of rheumatoid arthritis rising?: Results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum. 2010 62 6 1576 1582 10.1002/art.27425 20191579
    [Google Scholar]
  27. Raoof R. Willemen H.L.D.M. Eijkelkamp N. Divergent roles of immune cells and their mediators in pain. Rheumatology (Oxford) 2018 57 3 429 440 10.1093/rheumatology/kex308 28968842
    [Google Scholar]
  28. Anca P.S. Toth P.P. Kempler P. Rizzo M. Gender differences in the battle against COVID‐19: Impact of genetics, comorbidities, inflammation and lifestyle on differences in outcomes. Int. J. Clin. Pract. 2021 75 2 e13666 10.1111/ijcp.13666 32770758
    [Google Scholar]
  29. Ngo S.T. Steyn F.J. McCombe P.A. Gender differences in autoimmune disease. Front. Neuroendocrinol. 2014 35 3 347 369 10.1016/j.yfrne.2014.04.004 24793874
    [Google Scholar]
  30. Crowson C.S. Matteson E.L. Myasoedova E. Michet C.J. Ernste F.C. Warrington K.J. Davis J.M. III Hunder G.G. Therneau T.M. Gabriel S.E. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011 63 3 633 639 10.1002/art.30155 21360492
    [Google Scholar]
  31. Tanwar A. Thakur P. Chawla R. Ansari M.M. Curative remedies for rheumatoid arthritis: Herbal informatics approach for rational based selection of natural plant products. Indian J. Tradit. Knowl. 2017 16 1 128 133
    [Google Scholar]
  32. Innala L. Berglin E. Möller B. Ljung L. Smedby T. Södergren A. Magnusson S. Rantapää-Dahlqvist S. Wållberg-Jonsson S. Age at onset determines severity and choice of treatment in early rheumatoid arthritis: A prospective study. Arthritis Res. Ther. 2014 16 2 R94 10.1186/ar4540 24731866
    [Google Scholar]
  33. Watts R.A. Conaghan P.G. Denton C. Foster H. Isaacs J. Oxford textbook of rheumatology. OUP Oxford 2013 10.1093/med/9780199642489.001.0001
    [Google Scholar]
  34. Ding Q. Hu W. Wang R. Yang Q. Zhu M. Li M. Cai J. Rose P. Mao J. Zhu Y.Z. Signaling pathways in rheumatoid arthritis: Implications for targeted therapy. Signal Transduct. Target. Ther. 2023 8 1 68 10.1038/s41392‑023‑01331‑9 36797236
    [Google Scholar]
  35. Xin P. Xu X. Deng C. Liu S. Wang Y. Zhou X. Ma H. Wei D. Sun S. The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int. Immunopharmacol. 2020 80 106210 10.1016/j.intimp.2020.106210 31972425
    [Google Scholar]
  36. Simon L.S. Taylor P.C. Choy E.H. The Jak/STAT pathway: A focus on pain in rheumatoid arthritis. Semin. Arthritis Rheum. 2021 51 1 278 10.1016/j.semarthrit.2020.10.008
    [Google Scholar]
  37. Malemud C.J. The role of the JAK/STAT signal pathway in rheumatoid arthritis. Ther. Adv. Musculoskelet. Dis. 2018 10 5-6 117 127 10.1177/1759720X18776224 29942363
    [Google Scholar]
  38. Angelini J. Talotta R. Roncato R. Fornasier G. Barbiero G. Dal Cin L. Brancati S. Scaglione F. JAK-inhibitors for the treatment of rheumatoid arthritis: A focus on the present and an outlook on the future. Biomolecules 2020 10 7 1002 10.3390/biom10071002 32635659
    [Google Scholar]
  39. Banerjee S. Biehl A. Gadina M. Hasni S. Schwartz D.M. JAK–STAT signaling as a target for inflammatory and autoimmune diseases: Current and future prospects. Drugs 2017 77 5 521 546 10.1007/s40265‑017‑0701‑9 28255960
    [Google Scholar]
  40. Bousoik E. Montazeri Aliabadi H. “Do we know jack” about JAK? A closer look at JAK/STAT signaling pathway. Front. Oncol. 2018 8 287 10.3389/fonc.2018.00287 30109213
    [Google Scholar]
  41. Malemud C.J. Intracellular signaling pathways in rheumatoid arthritis. J. Clin. Cell. Immunol. 2013 4 160 10.4172/2155‑9899.1000160
    [Google Scholar]
  42. Leonard W.J. Lin J.X. Immunology C. Cytokine receptor signaling pathways. J. Allergy Clin. Immunol. 2000 105 5 877 888 10.1067/mai.2000.106899 10808165
    [Google Scholar]
  43. Abdou A.G. Maraee A. Yassien H. Sarhan M. Immunohistochemistry of Janus kinase 1 (JAK1) expression in vitiligo. J. Pathol. Transl. Med. 2018 52 6 363 368 10.4132/jptm.2018.09.18 30347972
    [Google Scholar]
  44. He X. Chen X. Zhang H. Xie T. Ye X.Y. Selective Tyk2 inhibitors as potential therapeutic agents: A patent review (2015–2018). Expert Opin. Ther. Pat. 2019 29 2 137 149 10.1080/13543776.2019.1567713 30621465
    [Google Scholar]
  45. Gao W. Dong X. Yang Z. Mao G. Xing W. Association between rs7574865 polymorphism in STAT4 gene and rheumatoid arthritis: An updated meta-analysis. Eur. J. Intern. Med. 2020 71 101 103 10.1016/j.ejim.2019.11.009 31757580
    [Google Scholar]
  46. Ralph J.A. Morand E.F. MAPK phosphatases as novel targets for rheumatoid arthritis. Expert Opin. Ther. Targets 2008 12 7 795 808 10.1517/14728222.12.7.795 18554149
    [Google Scholar]
  47. Sujitha S. Rasool M. MicroRNAs and bioactive compounds on TLR/MAPK signaling in rheumatoid arthritis. Clin. Chim. Acta 2017 473 106 115 10.1016/j.cca.2017.08.021 28842173
    [Google Scholar]
  48. Whitaker R.H. Cook J.G. Stress relief techniques: P38 MAPK determines the balance of cell cycle and apoptosis pathways. Biomolecules 2021 11 10 1444 10.3390/biom11101444 34680077
    [Google Scholar]
  49. Kanai T. Kondo N. Okada M. Sano H. Okumura G. Kijima Y. Ogose A. Kawashima H. Endo N. The JNK pathway represents a novel target in the treatment of rheumatoid arthritis through the suppression of MMP-3. J. Orthop. Surg. Res. 2020 15 1 87 10.1186/s13018‑020‑01595‑9 32131874
    [Google Scholar]
  50. Zhang L. Xiao H. Zhang F. Wu Y. Shu J. Li Y. Tai Y. Xu S. Xu J. Wei W. BAFF, involved in B cell activation through the NF-κB pathway, is related to disease activity and bone destruction in rheumatoid arthritis. Acta Pharmacol. Sin. 2021 42 10 1665 1675 10.1038/s41401‑020‑00582‑4 33483588
    [Google Scholar]
  51. Iwata S. Nakayamada S. Fukuyo S. Kubo S. Yunoue N. Wang S.P. Yoshikawa M. Saito K. Tanaka Y. Activation of Syk in peripheral blood B cells in patients with rheumatoid arthritis: A potential target for abatacept therapy. Arthritis Rheumatol. 2015 67 1 63 73 10.1002/art.38895 25303149
    [Google Scholar]
  52. Corneth O.B.J. Klein Wolterink R.G.J. Hendriks R.W. BTK signaling in B cell differentiation and autoimmunity. Curr. Top. Microbiol. Immunol. 2015 393 67 105 10.1007/82_2015_478 26341110
    [Google Scholar]
  53. Markman B. Dienstmann R. Tabernero J. Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs. Oncotarget 2010 1 7 530 543 10.18632/oncotarget.188 21317449
    [Google Scholar]
  54. Ersahin T. Tuncbag N. Cetin-Atalay R. The PI3K/AKT/mTOR interactive pathway. Mol. Biosyst. 2015 11 7 1946 1954 10.1039/C5MB00101C 25924008
    [Google Scholar]
  55. Tsai C.H. Liu S.C. Wang Y.H. Su C.M. Huang C.C. Hsu C.J. Tang C.H. Osteopontin inhibition of miR-129-3p enhances IL-17 expression and monocyte migration in rheumatoid arthritis. Biochim. Biophys. Acta, Gen. Subj. 2017 1861 2 15 22 10.1016/j.bbagen.2016.11.015 27851983
    [Google Scholar]
  56. Shoda H. Nagafuchi Y. Tsuchida Y. Sakurai K. Sumitomo S. Fujio K. Yamamoto K. Increased serum concentrations of IL-1 beta, IL-21 and Th17 cells in overweight patients with rheumatoid arthritis. Arthritis Res. Ther. 2017 19 1 111 10.1186/s13075‑017‑1308‑y 28569167
    [Google Scholar]
  57. Kwok S.K. Cho M.L. Park M.K. Oh H.J. Park J.S. Her Y.M. Lee S.Y. Youn J. Ju J.H. Park K.S. Kim S.I. Kim H.Y. Park S.H. Interleukin‐21 promotes osteoclastogenesis in humans with rheumatoid arthritis and in mice with collagen‐induced arthritis. Arthritis Rheum. 2012 64 3 740 751 10.1002/art.33390 21968544
    [Google Scholar]
  58. Dinesh P. Rasool M. Berberine inhibits IL-21/IL-21R mediated inflammatory proliferation of fibroblast-like synoviocytes through the attenuation of PI3K/Akt signaling pathway and ameliorates IL-21 mediated osteoclastogenesis. Cytokine 2018 106 54 66 10.1016/j.cyto.2018.03.005 29549724
    [Google Scholar]
  59. Zou L. Zhang G. Liu L. Chen C. Cao X. Cai J. Relationship between PI3K pathway and angiogenesis in CIA rat synovium. Am. J. Transl. Res. 2016 8 7 3141 3147 27508035
    [Google Scholar]
  60. Li X.F. Sun Y.Y. Bao J. Chen X. Li Y.H. Yang Y. Zhang L. Huang C. Wu B.M. Meng X.M. Li J. Functional role of PPAR-γ on the proliferation and migration of fibroblast-like synoviocytes in rheumatoid arthritis. Sci. Rep. 2017 7 1 12671 10.1038/s41598‑017‑12570‑6 28978936
    [Google Scholar]
  61. Yang Y. Wei C. Liu J. Ma D. Xiong C. Lin D. Wu A. Atorvastatin protects against postoperative neurocognitive disorder via a peroxisome proliferator-activated receptor-gamma signaling pathway in mice. J. Int. Med. Res. 2020 48 5 0300060520924251 10.1177/0300060520924251 32412807
    [Google Scholar]
  62. Klotz L. Burgdorf S. Dani I. Saijo K. Flossdorf J. Hucke S. Alferink J. Novak N. Beyer M. Mayer G. Langhans B. Klockgether T. Waisman A. Eberl G. Schultze J. Famulok M. Kolanus W. Glass C. Kurts C. Knolle P.A. The nuclear receptor PPARγ selectively inhibits Th17 differentiation in a T cell–intrinsic fashion and suppresses CNS autoimmunity. J. Exp. Med. 2009 206 10 2079 2089 10.1084/jem.20082771 19737866
    [Google Scholar]
  63. Xu Z. Wang G. Zhu Y. Liu R. Song J. Ni Y. Sun H. Yang B. Hou M. Chen L. Ji M. Fu Z. PPAR‐γ agonist ameliorates liver pathology accompanied by increasing regulatory B and T cells in high‐fat‐diet mice. Obesity (Silver Spring) 2017 25 3 581 590 10.1002/oby.21769 28150448
    [Google Scholar]
  64. Xia H. Chen L. Liu H. Sun Z. Yang W. Yang Y. Cui S. Li S. Wang Y. Song L. Abdelgawad A.F. Shang Y. Yao S. Protectin DX increases survival in a mouse model of sepsis by ameliorating inflammation and modulating macrophage phenotype. Sci. Rep. 2017 7 1 99 10.1038/s41598‑017‑00103‑0 28273909
    [Google Scholar]
  65. Li X. Yin S. Li H. Yang Y. Chen X. Song B. Wu S. Wu Y. Wang H. Li J. PPAR-γ alleviates the inflammatory response in TNF-α-induced fibroblast-like synoviocytes by binding to p53 in rheumatoid arthritis. Acta Pharmacol. Sin. 2023 44 2 454 464 10.1038/s41401‑022‑00957‑9 35918412
    [Google Scholar]
  66. Li C. Ding X.Y. Xiang D.M. Xu J. Huang X.L. Hou F.F. Zhou Q.G. Enhanced M1 and impaired M2 macrophage polarization and reduced mitochondrial biogenesis via inhibition of AMP kinase in chronic kidney disease. Cell. Physiol. Biochem. 2015 36 1 358 372 10.1159/000430106 25967974
    [Google Scholar]
  67. Erlandsson M.C. Töyrä Silfverswärd S. Nadali M. Turkkila M. Svensson M.N.D. Jonsson I.M. Andersson K.M.E. Bokarewa M.I. IGF-1R signalling contributes to IL-6 production and T cell dependent inflammation in rheumatoid arthritis. Biochim. Biophys. Acta Mol. Basis Dis. 2017 1863 9 2158 2170 10.1016/j.bbadis.2017.06.002 28583713
    [Google Scholar]
  68. Aletaha D. Neogi T. Silman A.J. Funovits J. Felson D.T. Bingham C.O. III Birnbaum N.S. Burmester G.R. Bykerk V.P. Cohen M.D. Combe B. Costenbader K.H. Dougados M. Emery P. Ferraccioli G. Hazes J.M.W. Hobbs K. Huizinga T.W.J. Kavanaugh A. Kay J. Kvien T.K. Laing T. Mease P. Ménard H.A. Moreland L.W. Naden R.L. Pincus T. Smolen J.S. Stanislawska-Biernat E. Symmons D. Tak P.P. Upchurch K.S. Vencovský J. Wolfe F. Hawker G. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 62 9 2569 2581 10.1002/art.27584 20872595
    [Google Scholar]
  69. Horneff G. Becker I.J.A.R.D. OP0143 serious infections in juvenile idiopathic arthritis patients upon TNF inhibitors depend on disease activity. 2014, 73(2), 114-115.
  70. Aggarwal R. Ringold S. Khanna D. Neogi T. Johnson S.R. Miller A. Brunner H.I. Ogawa R. Felson D. Ogdie A. Aletaha D. Feldman B.M. Distinctions between diagnostic and classification criteria? Arthritis Care Res. (Hoboken) 2015 67 7 891 897 10.1002/acr.22583 25776731
    [Google Scholar]
  71. Vyas S. Bhalla A.S. Ranjan P. Kumar S. Kumar U. Gupta A.K. Rheumatoid arthritis revisited–Advanced imaging review. Pol. Przegl. Radiol. Med. Nukl. 2016 81 629 635 10.12659/PJR.899317 28105245
    [Google Scholar]
  72. Carstensen S.M.D. Terslev L. Jensen M.P. Østergaard M. Future use of musculoskeletal ultrasonography and magnetic resonance imaging in rheumatoid arthritis. Curr. Opin. Rheumatol. 2020 32 3 264 272 10.1097/BOR.0000000000000709 32205568
    [Google Scholar]
  73. van Delft M.A.M. Huizinga T.W.J. An overview of autoantibodies in rheumatoid arthritis. J. Autoimmun. 2020 110 102392 10.1016/j.jaut.2019.102392 31911013
    [Google Scholar]
  74. Sieghart D. Platzer A. Studenic P. Alasti F. Grundhuber M. Swiniarski S. Horn T. Haslacher H. Blüml S. Smolen J. Steiner G. Determination of autoantibody isotypes increases the sensitivity of serodiagnostics in rheumatoid arthritis. Front. Immunol. 2018 9 876 10.3389/fimmu.2018.00876 29740454
    [Google Scholar]
  75. Rantapää-Dahlqvist S. de Jong B.A.W. Berglin E. Hallmans G. Wadell G. Stenlund H. Sundin U. van Venrooij W.J. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003 48 10 2741 2749 10.1002/art.11223 14558078
    [Google Scholar]
  76. Mun S. Lee J. Park M. Shin J. Lim M.K. Kang H.G. Serum biomarker panel for the diagnosis of rheumatoid arthritis. Arthritis Res. Ther. 2021 23 1 31 10.1186/s13075‑020‑02405‑7 33461622
    [Google Scholar]
  77. Lin Y.J. Anzaghe M. Schülke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells 2020 9 4 880 10.3390/cells9040880 32260219
    [Google Scholar]
  78. Singh R. Jadhav K. Vaghasiya K. Ray E. Shukla R. Verma R.K. New generation smart drug delivery systems for rheumatoid arthritis. 2023 29 13 984 1001 37038685
    [Google Scholar]
  79. Buttgereit F. Strand V. Lee E.B. Simon-Campos A. McCabe D. Genet A. Tammara B. Rojo R. Hey-Hadavi J. Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: A randomised, double-blind, multicentre, phase IIb study. RMD Open 2019 5 1 e000889 10.1136/rmdopen‑2018‑000889 31168411
    [Google Scholar]
  80. Wang Q. He L. Fan D. Liang W. Fang J. Improving the anti-inflammatory efficacy of dexamethasone in the treatment of rheumatoid arthritis with polymerized stealth liposomes as a delivery vehicle. J. Mater. Chem. B Mater. Biol. Med. 2020 8 9 1841 1851 10.1039/C9TB02538C 32016224
    [Google Scholar]
  81. Ingawale D.K. Mandlik S.K.J.I. New insights into the novel anti-inflammatory mode of action of glucocorticoids.Immunopharmacol Immunotoxicol., 2020, 42(2), 59-73. 10.1080/08923973.2020.1728765.
    [Google Scholar]
  82. Sarzi-Puttini P. Ceribelli A. Marotto D. Batticciotto A. Atzeni F. Systemic rheumatic diseases: From biological agents to small molecules. Autoimmun. Rev. 2019 18 6 583 592 10.1016/j.autrev.2018.12.009 30959214
    [Google Scholar]
  83. Littlejohn E.A. Monrad S.U. Early diagnosis and treatment of rheumatoid arthritis. Prim. Care 2018 45 2 237 255 10.1016/j.pop.2018.02.010 29759122
    [Google Scholar]
  84. Paglia M.D.G. Silva M.T. Lopes L.C. Barberato-Filho S. Mazzei L.G. Abe F.C. de Cássia Bergamaschi C. Use of corticoids and non-steroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review and network meta-analysis. PLoS One 2021 16 4 e0248866 10.1371/journal.pone.0248866 33826610
    [Google Scholar]
  85. Bindu S. Mazumder S. Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem. Pharmacol. 2020 180 114147 10.1016/j.bcp.2020.114147 32653589
    [Google Scholar]
  86. Bacchi S. Palumbo P. Sponta A. Coppolino M.F. Clinical pharmacology of non-steroidal anti-inflammatory drugs: A review. Antiinflamm. Antiallergy Agents Med. Chem. 2012 11 1 52 64 10.2174/187152312803476255 22934743
    [Google Scholar]
  87. Johnson A.G. Quinn D.I. Day R.O. Non‐steroidal anti‐inflammatory drugs. Med. J. Aust. 1995 163 3 155 158 10.5694/j.1326‑5377.1995.tb127972.x 7643770
    [Google Scholar]
  88. Ling S. Bluett J. Barton A. Prediction of response to methotrexate in rheumatoid arthritis. Expert Rev. Clin. Immunol. 2018 14 5 419 429 10.1080/1744666X.2018.1465409 29667454
    [Google Scholar]
  89. Moran R.G. Folate antimetabolites inhibitory to de novo purine synthesis. Cancer Treat Res., 1992 58 65 87 10.1007/978‑1‑4615‑3876‑9_4
    [Google Scholar]
  90. Wang W. Zhou H. Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review. Eur. J. Med. Chem. 2018 158 502 516 10.1016/j.ejmech.2018.09.027 30243154
    [Google Scholar]
  91. Belani P.J. Kavadichanda C.G. Negi V.S. Comparison between leflunomide and sulfasalazine based triple therapy in methotrexate refractory rheumatoid arthritis: An open-label, non-inferiority randomized controlled trial. Rheumatol. Int. 2022 42 5 771 782 10.1007/s00296‑021‑04994‑1 34586472
    [Google Scholar]
  92. Law S.T. Taylor P.C. Role of biological agents in treatment of rheumatoid arthritis. Pharmacol. Res. 2019 150 104497 10.1016/j.phrs.2019.104497 31629903
    [Google Scholar]
  93. Keystone E.C. Genovese M.C. Klareskog L. Hsia E.C. Hall S.T. Miranda P.C. Pazdur J. Bae S-C. Palmer W. Zrubek J. Wiekowski M. Visvanathan S. Wu Z. Rahman M.U. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD Study. Ann. Rheum. Dis. 2009 68 6 789 796 10.1136/ard.2008.099010 19066176
    [Google Scholar]
  94. Maini R. St Clair E.W. Breedveld F. Furst D. Kalden J. Weisman M. Smolen J. Emery P. Harriman G. Feldmann M. Lipsky P. Infliximab (chimeric anti-tumour necrosis factor α 441 monoclonal antibody) versus placebo in rheumatoid arthritis patients 442 receiving concomitant methotrexate: A randomised phase III 443 trial. 1999 354 9194 1932 1939 10.1016/S0140‑6736(99)05246‑0 10622295
  95. Zavvar M. Assadiasl S. Soleimanifar N. Pakdel F.D. Abdolmohammadi K. Fatahi Y. Abdolmaleki M. Baghdadi H. Tayebi L. Nicknam M.H. Gene therapy in rheumatoid arthritis: Strategies to select therapeutic genes. J. Cell. Physiol. 2019 234 10 16913 16924 10.1002/jcp.28392 30809802
    [Google Scholar]
  96. Feng N. Guo F. Nanoparticle-siRNA: A potential strategy for 453 rheumatoid arthritis therapy? J. Control Release., 2020 325 380 393 10.1016/j.jconrel.2020.07.006.
  97. Chang C. Xu L. Zhang R. Jin Y. Jiang P. Wei K. Xu L. Shi Y. Zhao J. Xiong M. Guo S. He D. MicroRNA-mediated epigenetic regulation of rheumatoid arthritis susceptibility and pathogenesis. Front. Immunol. 2022 13 838884 10.3389/fimmu.2022.838884 35401568
    [Google Scholar]
  98. Song P. Yang C. Thomsen J.S. Dagnæs-Hansen F. Jakobsen M. Brüel A. Deleuran B. Kjems J. Lipidoid-siRNA nanoparticle-mediated IL-1β gene silencing for systemic arthritis therapy in a mouse model. Mol. Ther. 2019 27 8 1424 1435 10.1016/j.ymthe.2019.05.002 31153827
    [Google Scholar]
  99. Sun X. Dong S. Li X. Yu K. Sun F. Lee R.J. Li Y. Teng L. Delivery of siRNA using folate receptor-targeted pH-sensitive polymeric nanoparticles for rheumatoid arthritis therapy. Nanomedicine (Lond.) 2019 20 102017 10.1016/j.nano.2019.102017 31128293
    [Google Scholar]
  100. Shrestha S. Zhao J. Yang C. Zhang J. Iguratimod combination therapy compared with methotrexate monotherapy for the treatment of rheumatoid arthritis: A systematic review and meta-analysis. Clin. Rheumatol. 2021 40 10 4007 4017 10.1007/s10067‑021‑05746‑z 33914203
    [Google Scholar]
  101. Tang Q. Yin D. Wang Y. Du W. Qin Y. Ding A. Li H. Cancer stem cells and combination therapies to eradicate them. Curr. Pharm. Des. 2020 26 17 1994 2008 32250222
    [Google Scholar]
  102. Xiao S. Tang Y. Lv Z. Lin Y. Chen L. Nanomedicine: Advantages for their use in rheumatoid arthritis theranostics. J. Control. Release 2019 316 302 316 10.1016/j.jconrel.2019.11.008 31715278
    [Google Scholar]
  103. Damjanov N. Kauffman R.S. Spencer-Green G.T. Efficacy, pharmacodynamics, and safety of VX‐702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double‐blind, placebo‐controlled clinical studies. Arthritis Rheum. 2009 60 5 1232 1241 10.1002/art.24485 19404957
    [Google Scholar]
  104. Genovese M.C. Cohen S.B. Wofsy D. Weinblatt M. Firestein G.S. Brahn E. Strand V. Baker D.G. Tong S. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J. Rheumatol. 2011 38 5 846 854 10.3899/jrheum.100602 21285160
    [Google Scholar]
  105. Bullock J. Rizvi S.A.A. Saleh A.M. Ahmed S.S. Do D.P. Ansari R.A. Ahmed J. Rheumatoid arthritis: A brief overview of the treatment. Med. Princ. Pract. 2018 27 6 501 507 10.1159/000493390 30173215
    [Google Scholar]
  106. Schjerning A.M. McGettigan P. Gislason G. Cardiovascular effects and safety of (non-aspirin) NSAIDs. Nat. Rev. Cardiol. 2020 17 9 574 584 10.1038/s41569‑020‑0366‑z 32322101
    [Google Scholar]
  107. Salliot C. van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic literature research. Ann. Rheum. Dis. 2009 68 7 1100 1104 10.1136/ard.2008.093690 19060002
    [Google Scholar]
  108. Sinniah A. Yazid S. Flower R.J. From NSAIDs to glucocorticoids and beyond. Cells 2021 10 12 3524 10.3390/cells10123524 34944032
    [Google Scholar]
  109. Strehl C. van der Goes M.C. Bijlsma J.W.J. Jacobs J.W.G. Buttgereit F. Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis. Expert Opin. Investig. Drugs 2017 26 2 187 195 10.1080/13543784.2017.1276562 28043173
    [Google Scholar]
  110. Cañete J.D. Hernández M.V. Sanmartí R. Safety profile of biological therapies for treating rheumatoid arthritis. Expert Opin. Biol. Ther. 2017 17 9 1089 1103 10.1080/14712598.2017.1346078 28657381
    [Google Scholar]
  111. Panchal N.K. Prince Sabina E. Toxicology C. Non-steroidal anti-inflammatory drugs (NSAIDs): A current insight into its molecular mechanism eliciting organ toxicities. Food Chem. Toxicol. 2023 172 113598 10.1016/j.fct.2022.113598 36608735
    [Google Scholar]
  112. Zhou S. Jiang W. Chen G. Huang G. Design and synthesis of novel double-ring conjugated enones as potent anti-rheumatoid arthritis agents. ACS Omega 2022 7 48 44065 44077 10.1021/acsomega.2c05492 36506211
    [Google Scholar]
  113. Fang X. Liu C. Zhang K. Yang W. Wu Z. Shen S. Ma Y. Lu X. Chen Y. Lu T. Hu Q. Jiang Y. Discovery of orally active 1,4,5,6,8-pentaazaacenaphthylens as novel, selective, and potent covalent BTK inhibitors for the treatment of rheumatoid arthritis. Eur. J. Med. Chem. 2023 246 114940 10.1016/j.ejmech.2022.114940 36462441
    [Google Scholar]
  114. Pallavi H. Vivek H.K. Khanum S.A. Jiang Y. Design, docking, synthesis, and characterization of novel N‘(2-phenoxyacetyl) nicotinohydrazide and N’(2-phenoxyacetyl) isonicotinohydrazide derivatives as anti-inflammatory and analgesic agents. J. Mol. Struct. 2022 1247 131404 10.1016/j.molstruc.2021.131404
    [Google Scholar]
  115. Pan T. He M. Deng L. Li J. Fan Y. Hao X. Mu S. Design, synthesis, and evaluation of the COX-2 inhibitory activities of new 1,3-Dihydro-2H-indolin-2-one derivatives. Molecules 2023 28 12 4668 10.3390/molecules28124668 37375225
    [Google Scholar]
  116. Miao Y. Yang J. Yun Y. Sun J. Wang X. Synthesis and anti-rheumatoid arthritis activities of 3-(4-aminophenyl)-coumarin derivatives. J. Enzyme Inhib. Med. Chem. 2021 36 1 450 461 10.1080/14756366.2021.1873978 33557646
    [Google Scholar]
  117. Shu L. Chen C. Huan X. Huang H. Wang M. Zhang J. Yan Y. Liu J. Zhang T. Zhang D. Design, synthesis, and pharmacological evaluation of 4- or 6-phenyl-pyrimidine derivatives as novel and selective Janus kinase 3 inhibitors. Eur. J. Med. Chem. 2020 191 112148 10.1016/j.ejmech.2020.112148 32097841
    [Google Scholar]
  118. Zhang C. Pei H. He J. Zhu J. Li W. Niu T. Xiang M. Chen L. Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis. Eur. J. Med. Chem. 2019 169 121 143 10.1016/j.ejmech.2019.02.077 30875504
    [Google Scholar]
  119. El-Miligy M.M.M. Hazzaa A.A. El-Messmary H. Nassra R.A. El-Hawash S.A.M. New hybrid molecules combining benzothiophene or benzofuran with rhodanine as dual COX-1/2 and 5-LOX inhibitors: Synthesis, biological evaluation and docking study. Bioorg. Chem. 2017 72 102 115 10.1016/j.bioorg.2017.03.012 28390993
    [Google Scholar]
  120. Harizi H. Corcuff J.B. Gualde N. Arachidonic-acid-derived eicosanoids: Roles in biology and immunopathology. Trends Mol. Med. 2008 14 10 461 469 10.1016/j.molmed.2008.08.005 18774339
    [Google Scholar]
  121. Yao X. Sun X. Jin S. Yang L. Xu H. Rao Y. Discovery of 4-aminoquinoline-3-carboxamide derivatives as potent reversible Bruton’s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. J. Med. Chem. 2019 62 14 6561 6574 10.1021/acs.jmedchem.9b00329 31260299
    [Google Scholar]
  122. Kaur M. Singh M. Silakari O. Oxindole-based SYK and JAK3 dual inhibitors for rheumatoid arthritis: Designing, synthesis and biological evaluation. Future Med. Chem. 2017 9 11 1193 1211 10.4155/fmc‑2017‑0037 28722479
    [Google Scholar]
  123. Yu R.N. Chen C.J. Shu L. Yin Y. Wang Z.J. Zhang T.T. Zhang D.Y. Structure-based design and synthesis of pyrimidine-4,6-diamine derivatives as Janus kinase 3 inhibitors. Bioorg. Med. Chem. 2019 27 8 1646 1657 10.1016/j.bmc.2019.03.009 30853331
    [Google Scholar]
  124. Chiasson A.I. Robichaud S. Ndongou Moutombi F.J. Hébert M.P.A. Mbarik M. Surette M.E. Touaibia M. New zileuton-hydroxycinnamic acid hybrids: Synthesis and structure-activity relationship towards 5-lipoxygenase inhibition. Molecules 2020 25 20 4686 10.3390/molecules25204686 33066378
    [Google Scholar]
/content/journals/ctmc/10.2174/0115680266346339250328153358
Loading
Rheumatoid Arthritis: Pathogenesis, Therapeutic Strategies, Advances, and Structural Activity Relationships of Synthesized Agents
Bentham Science Publishers ; https://doi.org/10.2174/0115680266346339250328153358
/content/journals/ctmc/10.2174/0115680266346339250328153358
/content/journals/ctmc/10.2174/0115680266346339250328153358
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Docking ; Phenyl pyrimidines ; Rheumatoid arthritis ; JAK inhibitors ; SARs ; MAPK inhibitors ; BTK inhibitors ; Benzothiopenes

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test